GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Viracta Therapeutics
Viracta is an oncology company developing drugs to treat cancers associated with the Epstein-Barr virus. Its stock price is highly volatile and driven by news of clinical trials.
Share prices of companies in the market segment - Cancer cure
Viracta Therapeutics is an oncology company developing drugs to treat cancers associated with the Epstein-Barr virus. We categorize it as a "Cancer Treatment" company. The chart below shows how investors value targeted therapies for virus-associated tumors.
Broad Market Index - GURU.Markets
Viracta Therapeutics is an oncology company developing drugs to treat cancers associated with the Epstein-Barr virus. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Viracta shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VIRX - Daily change in the company's share price Viracta Therapeutics
For Viracta Therapeutics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
Viracta Therapeutics is developing targeted therapies for cancers associated with the Epstein-Barr virus. This is a highly specialized and risky niche in oncology. The chart below illustrates the volatility typical of the biotech sector, providing context for analyzing VIRX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Viracta is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Viracta Therapeutics
Viracta Therapeutics' year-over-year performance is a story about its targeted therapy development. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which targets virus-associated cancers, could offer new hope for patients for whom other treatment options are lacking.
Annual dynamics of market capitalization of the market segment - Cancer cure
Viracta, a late-stage biotech company, develops drugs to treat virus-related cancers. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viracta Therapeutics is a biotech company whose value is based on the hope of developing a new cancer drug. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on clinical trial success. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Viracta Therapeutics
Viracta is a late-stage oncology company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its drug for the treatment of virus-associated lymphomas is the main highlight.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Viracta Therapeutics is an oncology company developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. The chart below illustrates the overall dynamics of the biotech sector, where Viracta occupies a unique niche by targeting virus-induced tumors.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viracta Therapeutics is a biotech company developing drugs to treat cancer associated with the Epstein-Barr virus. Its shares are buoyed by anticipation of trial results. Positive data can trigger explosive growth, while failures can lead to a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Viracta Therapeutics
Viracta Therapeutics, a biopharmaceutical company developing therapies for virus-related cancers, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and regulatory decisions, reflecting the potential of its targeted approach.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Viracta Therapeutics shares, like those of the entire oncology biotech sector, are moving on broad sector news and sentiment. Breakthroughs in the treatment of virus-associated tumors could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Viracta Therapeutics is a biotech company developing cancer therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that VIRX's performance is largely uncorrelated with the market, moving on its own unique news.
Market capitalization of the company, segment and market as a whole
VIRX - Market capitalization of the company Viracta Therapeutics
The Viracta Therapeutics chart is a financial map of the fight against Epstein-Barr virus-associated cancer. The company's market cap reflects the hopes for its targeted therapy, which "turns on" the virus within tumors, making them vulnerable. Its dynamics are a barometer of progress in clinical trials of this innovative strategy.
VIRX - Share of the company's market capitalization Viracta Therapeutics within the market segment - Cancer cure
Viracta Therapeutics targets cancers caused by the Epstein-Barr virus. The company's market capitalization in the oncology segment reflects the market's confidence in its targeted approach. The company's market capitalization is an indicator of the potential of its therapy in combating a wide range of malignancies.
Market capitalization of the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the growing interest in the connection between viruses and cancer and the search for new treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Viracta is an oncology company developing targeted therapies for the treatment of cancer associated with the Epstein-Barr virus. Its market capitalization chart tells the story of precision engineering, demonstrating how a drug targeting a specific tumor cause can create value.
Book value capitalization of the company, segment and market as a whole
VIRX - Book value capitalization of the company Viracta Therapeutics
For Viracta Therapeutics, an oncology company, book value is its equity. The chart below shows its financial resources for conducting clinical trials. This level is an indicator of its ability to finance the development of innovative therapies for virus-associated tumors.
VIRX - Share of the company's book capitalization Viracta Therapeutics within the market segment - Cancer cure
Viracta Therapeutics is a biotech company developing targeted therapies for cancers associated with the Epstein-Barr virus. Its primary asset is research and development. The company's tangible asset share will be low, reflecting its focus on R&D.
Market segment balance sheet capitalization - Cancer cure
Below you can see the overall book value of the biotech sector. Compared to this, Viracta, which develops targeted cancer therapies, looks "light." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Viracta Therapeutics develops targeted therapies for cancers associated with the Epstein-Barr virus. The company's assets are not drugs, but intellectual property and research data. The company's balance sheet is the value of a "sniper rifle" aimed at a very specific cause of certain types of cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Viracta Therapeutics
Viracta's balance sheet is its cash and patents. Its market capitalization is the bet on the success of its drug for treating viral-associated cancers. The MvsBCap_Co chart shows how many times the "hope" for targeted therapy is worth compared to the company's cash in hand.
Market to book capitalization ratio in a market segment - Cancer cure
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. Its value lies in this niche approach. The chart shows a speculative estimate of its potential, which is highly dependent on the success of its clinical programs.
Market to book capitalization ratio for the market as a whole
Viracta Therapeutics develops drugs to treat virus-associated cancers. Its value to investors is derived from the potential of its scientific platform. This metric demonstrates a classic biotech situation: the market is willing to pay a high price, significantly exceeding book value, for the chance to obtain an effective treatment for serious diseases.
Debts of the company, segment and market as a whole
VIRX - Company debts Viracta Therapeutics
For Viracta Therapeutics, a company developing targeted therapies for virus-associated cancers, debt is key to advancing its drugs. This chart shows how the company is raising capital to conduct clinical trials of its innovative approach. In this niche of oncology, debt is an investment in a potential new standard of treatment.
Market segment debts - Cancer cure
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This is an innovative approach in oncology. This chart shows how the clinical-stage biotech company funds its specialized and capital-intensive research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Viracta Therapeutics
Viracta Therapeutics is an oncology company developing targeted therapies. Its financial model is typical of biotech: heavy spending today for potential profits tomorrow. This chart shows its debt load, which is a measure of risk: the higher the debt, the greater the dependence on successful clinical trials.
Market segment debt to market segment book capitalization - Cancer cure
Viracta Therapeutics is an oncology company developing drugs to treat cancer associated with the Epstein-Barr virus. This targeted approach requires investment in research. The chart shows how the company's debt load relates to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Viracta Therapeutics (VIRX) is an oncology company developing targeted therapies for the treatment of cancer associated with the Epstein-Barr virus. While in clinical trials, the company has no stable revenue. This chart shows the overall market debt load, clearly illustrating why Viracta relies on investor capital rather than debt.
P/E of the company, segment and market as a whole
P/E - Viracta Therapeutics
This metric for Viracta Therapeutics, a company developing treatments for Epstein-Barr virus-associated cancers, is a bet on a targeted approach. There is no price-to-earnings ratio. The company's valuation depends on the success of its drug in clinical trials. The chart reflects progress in this narrow but important niche of oncology.
P/E of the market segment - Cancer cure
This chart illustrates the average P/E for biotech companies. For Viracta, with its targeted approach to treating virus-associated cancers, it serves as a backdrop. It shows the overall level of optimism in oncology, providing context for Viracta's valuation, which is betting on the success of its highly specialized platform.
P/E of the market as a whole
Viracta Therapeutics is developing a targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This is a niche but innovative approach to oncology. The company's valuation depends on the success of clinical trials. This chart shows overall interest in oncology. It helps understand how the market views the potential of this specific approach and how clinical news impacts its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Viracta Therapeutics
Viracta Therapeutics is developing targeted therapy for virus-associated cancer. For a clinical-stage company, this chart serves as a barometer of expectations. It reflects analysts' assessments of the likelihood of success in clinical programs and the potential market size for its drugs, incorporating these forecasts into future profitability estimates.
%20P%2FE%20Viracta%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Viracta-Therapeutics&v=1772632139924 "Chart of the company's future (projected) P/E Viracta Therapeutics")
Future (projected) P/E of the market segment - Cancer cure
Viracta Therapeutics, Inc. is developing a targeted therapy for cancer associated with the Epstein-Barr virus. This chart shows average expectations for the biotech sector. Viracta's position may indicate the extent to which investors believe in its unique approach and the potential of its drug for treating various types of lymphoma and other tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772632139943 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Viracta Therapeutics is an oncology company targeting virus-associated tumors. For a company in the development stage, research data is key. This chart of overall market expectations provides a general overview, but for Viracta, lab news is paramount.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632139977 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Viracta Therapeutics
Viracta Therapeutics is an oncology company developing targeted therapies for virus-associated cancers. This chart illustrates their focused approach to fighting cancer. Revenue growth will depend on the success of their lead drug in clinical trials and partnerships with major pharmaceutical companies for its commercialization.
Profit of companies in the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. Profitability in this niche oncology sector, as this chart shows, is determined by the uniqueness of its approach. For VIRX, focusing on a specific viral cause of cancer allows for the creation of a highly precise drug that can be highly effective for a specific group of patients.
Overall market profit
Viracta Therapeutics, which focuses on treating cancer associated with the Epstein-Barr virus, addresses a specific medical need. Demand for its drugs is not dependent on the state of the economy, as illustrated by this chart. The company's key drivers are progress in clinical trials and regulatory approval, not overall corporate profitability.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Viracta Therapeutics
Viracta Therapeutics is developing a targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This chart reflects analyst forecasts, which assess the potential of its unique approach. The trend reflects market confidence in the success of clinical trials.
%20profit%20of%20the%20company%20Viracta%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Viracta-Therapeutics&v=1772632140170 "Graph of future (projected) profit of the company Viracta Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This is a niche but important approach in oncology. This chart shows the revenue forecast for the cancer treatment sector, reflecting expectations for the development of personalized medicine targeting specific viral tumor drivers.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772632140184 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Viracta Therapeutics is an oncology company developing targeted therapies. Its value is determined by the results of clinical trials and the potential of its drugs. The overall economic outlook, presented in the chart, influences the company through investor sentiment. During periods of pessimism, raising capital for risky biotech projects becomes more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632140199 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Viracta Therapeutics
Viracta Therapeutics is an oncology company focused on treating cancers associated with the Epstein-Barr virus. Being in the clinical stage, it has no stable revenue. The chart reflects investor valuations of its lead drug. This is a bet on successful clinical trial results and the potential of its targeted treatment approach.
P/S market segment - Cancer cure
Viracta Therapeutics is developing a targeted therapy for cancer associated with the Epstein-Barr virus. The chart shows the average revenue estimate in the biotech sector, providing insight into how highly investors value its unique approach, which targets the viral cause of certain cancers.
P/S of the market as a whole
Viracta Therapeutics develops targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This is a highly specialized approach in oncology. The graph of average market revenue estimates clearly demonstrates that investors are not evaluating current revenue, but the company's potential to carve out a unique niche in cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Viracta Therapeutics
Viracta Therapeutics is an oncology company developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. The chart shows the forward market valuation of its research and development pipeline, based on potential future sales of its drug, which addresses a significant unmet medical need.
%20P%2FS%20Viracta%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Viracta-Therapeutics&v=1772632140269 "The graph of the company's future (projected) P/S Viracta Therapeutics")
Future (projected) P/S of the market segment - Cancer cure
Viracta Therapeutics develops targeted therapies for virus-associated cancers. This chart shows the median future revenue estimates for cancer treatment companies. This helps assess how highly investors value Viracta's unique approach and the commercial potential of its lead drug candidate compared to other oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772632140307 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Viracta Therapeutics is an oncology company focused on virus-associated cancers. Its future depends on the success of its lead drug. This indicator of overall revenue expectations is irrelevant. Viracta's entire value lies in its clinical trial results and the potential of its unique treatment approach.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632140360 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Viracta Therapeutics
Viracta Therapeutics is an oncology company developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. Being in the clinical stage, it typically does not generate revenue from drug sales. Any revenue in this chart likely comes from upfront payments from strategic research partners.
Sales of companies in the market segment - Cancer cure
Viracta Therapeutics is an oncology company developing a new approach to treating Epstein-Barr virus (EBV)-associated cancer. Their drug activates antitumor activity in EBV-infected cancer cells. This chart shows total revenue in the sector, reflecting progress in developing targeted therapies for specific cancer subtypes.
Overall market sales
Viracta Therapeutics is a biopharmaceutical company treating virus-associated cancers. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Viracta Therapeutics
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. Its future depends on the success of this innovative approach in clinical trials. This chart reflects the market's assessment of the likelihood of commercial success for its anticancer drugs.
%20sales%20of%20the%20company%20Viracta%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Viracta-Therapeutics&v=1772632140484 "Schedule of future (projected) sales of the company Viracta Therapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus. This niche approach targets a specific tumor cause. This graph illustrates the outlook for the entire cancer treatment industry. The company's success depends on the effectiveness of its unique approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772632140613 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Viracta Therapeutics is developing a targeted therapy for virus-associated cancer. The company's prospects depend on the success of clinical trials and regulatory approval. This timeline, reflecting the overall investment climate in biotechnology, impacts Viracta's ability to raise capital to fund expensive drug development stages.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632140634 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Viracta Therapeutics
Viracta Therapeutics is an oncology company developing targeted therapies for virus-associated cancers. Its financial performance reflects the clinical development stage with high R&D expenditures. This chart illustrates the company's investment path to developing potentially profitable and life-saving drugs.
Market segment marginality - Cancer cure
Viracta Therapeutics is an oncology company developing targeted therapies for the treatment of cancers associated with the Epstein-Barr virus. This chart shows the average profitability in the oncology sector. Its unique "hit and kill" approach offers the potential to develop highly effective drugs and achieve above-average profitability.
Market marginality as a whole
Viracta Therapeutics is a biotech company focused on treating virus-associated cancers. Its financial model is based on investing in clinical research and development. This total corporate return chart clearly illustrates the gap between established profitable businesses and companies operating at the cutting edge of science.
Employees in the company, segment and market as a whole
Number of employees in the company Viracta Therapeutics
Viracta Therapeutics is developing innovative treatments for virus-associated cancers. Scientific breakthroughs require talented individuals. This chart shows the size of the team of researchers and clinicians working to advance its lead drug through clinical trials, aiming to offer new options for cancer patients.
Share of the company's employees Viracta Therapeutics within the market segment - Cancer cure
Viracta Therapeutics targets cancers associated with the Epstein-Barr virus. This is a unique approach in oncology. This chart shows the company's concentration of specialists in the narrow niche of virus-associated cancers. It allows one to assess its scientific strength and potential for developing therapies for patients who previously had no specific treatment options.
Number of employees in the market segment - Cancer cure
Viracta Therapeutics, Inc. is an oncology company developing targeted therapies for the treatment of virus-associated cancers. The growth of its scientific and clinical team, visible in the chart, is a leading indicator. This increase in staffing indicates that its lead program is successfully advancing through clinical trials.
Number of employees in the market as a whole
Viracta Therapeutics targets cancers associated with the Epstein-Barr virus. This chart shows the biotech company's progress in the clinical stage. The growth of its small team of scientists and doctors is directly linked to progress in trials of their targeted therapy, which could become a new standard of care for a specific group of patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Viracta Therapeutics (VIRX)
Viracta Therapeutics develops drugs to treat viral-associated oncology diseases. This metric is especially important for the company during the clinical development stage. It reflects not current labor productivity, but the concentrated value of its intellectual property. The market evaluates the potential of their scientific platform, which is being developed by a relatively small team of scientists.
%20of%20the%20company%20Viracta%20Therapeutics%20(VIRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Viracta-Therapeutics-VIRX&v=1772632140824 "Chart of market capitalization per employee (in thousands of dollars) of the company Viracta Therapeutics (VIRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapies for cancers associated with the Epstein-Barr virus. This is a highly specialized field where value is created by the scientific breakthroughs of a small team. This chart shows how investors value the company's intellectual capital per scientist.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772632140881 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Viracta Therapeutics is developing targeted therapy for the treatment of cancer associated with the Epstein-Barr virus. The chart illustrates the valuation of this niche oncology company. The high market capitalization per employee reflects the potential of their approach, which targets the specific cause of certain tumor types.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632140916 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Viracta Therapeutics (VIRX)
Viracta Therapeutics is an oncology company developing treatments for cancers associated with the Epstein-Barr virus. The company has an approved drug. This chart illustrates the commercial success of this niche strategy. Revenue per employee depends on the price and demand for their drug.
%20Chart%20Viracta%20Therapeutics%20(VIRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Viracta-Therapeutics-VIRX&v=1772632140929 "Company Profit Per Employee (in thousands of dollars) Chart Viracta Therapeutics (VIRX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Viracta Therapeutics is developing targeted therapy for the treatment of cancers associated with the Epstein-Barr virus (EBV). This is a niche approach in oncology. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company is investing in its scientific programs to commercialize this unique approach to treating EBV-positive tumors.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772632140963 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Viracta Therapeutics is a clinical-stage oncology company specializing in the treatment of cancers associated with the Epstein-Barr virus (EBV). The company is not yet profitable. This chart shows the R&D investment (loss) per scientist, which is typical for a biotech company working on targeted therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632140967 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Viracta Therapeutics (VIRX)
Viracta Therapeutics specializes in treating virus-associated cancers. This chart is an important indicator for a biotech company. Growing revenue per employee typically signals a strategic partnership that monetizes years of research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Viracta-Therapeutics-VIRX&v=1772632140989 "Sales chart per company employee Viracta Therapeutics (VIRX)")
Sales per employee in the market segment - Cancer cure
Viracta (VIRX) is a clinical-stage oncology company specializing in the treatment of cancers associated with the Epstein-Barr virus. The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Viracta is a biotech company focused on treating virus-related cancers. This metric is expectedly low at the clinical development stage. The company is investing in its research staff without a commercial product. This timeline is important for tracking the future transition to commercialization and assessing the potential impact of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Viracta Therapeutics (VIRX)
Viracta (VIRX) is an oncology company developing therapies for cancers associated with the Epstein-Barr virus (EBV). Their approach is to "wake up" the virus to make the tumor vulnerable. This metric measures skepticism. "Bears" doubt the effectiveness of this niche strategy or the success of their clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Viracta-Therapeutics-VIRX&v=1772632141077 "Short Shares Chart for the Company Viracta Therapeutics (VIRX)")
Shares shorted by market segment - Cancer cure
Viracta Therapeutics is an oncology company developing a therapy for cancers associated with the Epstein-Barr virus. This is a targeted treatment approach. This chart shows the total volume of short positions across the entire oncology-focused biotech sector. It demonstrates the overall investor confidence in the success of new cancer treatments. The increase in short positions in the sector is a negative sign for the entire industry.
Shares shorted by the overall market
Viracta Therapeutics is a clinical-stage biotech focused on cancer. When this chart shows rising fears, speculative, pre-profitable companies are the first to suffer. Investors aren't willing to wait years for FDA approval. They see Viracta as a money-burner and are selling off shares, fearing a lack of capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Viracta Therapeutics (VIRX)
Viracta Therapeutics (VIRX) is developing a targeted therapy for cancers associated with the Epstein-Barr virus (EBV). This is a niche but important approach in oncology. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) in anticipation of data or "oversold" (below 30) amid delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Viracta-Therapeutics-VIRX&v=1772632141242 "RSI 14 indicator chart for the company's stock Viracta Therapeutics (VIRX)")
RSI 14 Market Segment - Cancer cure
Viracta is a "biotech" EBV-cancer "killer." Their "thing" is a combo therapy (nanatinostat + valganciclovir) that "activates" the Epstein-Barr virus (EBV) inside the tumor and "kills" it (lymphoma). The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is VIRX's growth due to their R&D, or is the entire biotech industry "overheated"?
RSI 14 for the overall market
Viracta Therapeutics (VIRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VIRX (Viracta Therapeutics)
Viracta Therapeutics is an oncology company developing a therapy (nanatinostat) for the treatment of cancers associated with the Epstein-Barr virus (EBV). This chart shows the analysts' average 12-month forecast, representing their collective bet that this "viral" approach to oncology will be successful.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VIRX-Viracta-Therapeutics&v=1772632141426 "A chart showing analyst consensus forecasts for the expected stock price. VIRX (Viracta Therapeutics)")
The difference between the consensus estimate and the actual stock price VIRX (Viracta Therapeutics)
Viracta (VIRX) is a biotech company developing a "virus-activated" therapy (Nana-val) for the treatment of Epstein-Barr virus (EBV)-associated cancers. This chart shows the difference between the market valuation and the consensus estimate. It reveals whether experts believe in this "sniper" oncology R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VIRX-Viracta-Therapeutics&v=1772632141481 "A chart showing the difference between the consensus forecast and the actual stock price. VIRX (Viracta Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Viracta Therapeutics is a biotech company developing a combo drug for cancers associated with the Epstein-Barr virus (EBV). This chart shows analysts' overall expectations for the oncology sector. It reflects whether experts believe this antiviral cancer therapy will be successful.
Analysts' consensus forecast for the overall market share price
Viracta Therapeutics (VIRX) – "viral" oncology. They have developed a "smart" drug that "switches on" and kills only those cancer cells infected with the Epstein-Barr virus. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but high-risk, R&D platforms in oncology.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Viracta Therapeutics
Viracta Therapeutics is developing a new approach to treating Epstein-Barr virus (EBV)-associated cancers. Their strategy is to "reawaken" the virus in tumors, making them susceptible to therapy. This chart is an integrated assessment that weighs the innovation and risk of this scientific approach, as well as clinical trial data for their lead candidate.
AKIMA Market Segment Index - Cancer cure
Viracta Therapeutics (VIRX) is a viral cancer treatment company. They specialize in cancers caused by the Epstein-Barr virus (EBV). Their drug activates EBV within the tumor, killing it. This chart compares their composite index to the average for the cancer treatment sector.
The AKIM Index for the overall market
Viracta Therapeutics is a precision oncology company targeting cancer-associated viruses (Epstein-Barr virus). Its key asset is Nana-val. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this innovative lymphoma treatment platform.
